<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="232">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515279</url>
  </required_header>
  <id_info>
    <org_study_id>ML22273</org_study_id>
    <nct_id>NCT02515279</nct_id>
  </id_info>
  <brief_title>An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria</brief_title>
  <official_title>A Non-Interventional Trial of Pegasys/Copegus in HCV Patients for 12 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>N/A: Local health authority approval not required</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This noninterventional, open-label study will observe the safety and tolerability of
      peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for
      HCV infection according to routine practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained virologic response (SVR) rate</measure>
    <time_frame>At 24 weeks following completion of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">463</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Peginterferon alfa-2a + Ribavirin</arm_group_label>
    <description>Participants with HCV will receive peginterferon alfa-2a in combination with ribavirin at the discretion of the prescribing physician and according to local label and product information. Due to the observational nature of the study, no medication will be provided by the sponsor.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll Austrian participants receiving peginterferon alfa-2a and ribavirin
        for HCV infection according to routine practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ongoing treatment with peginterferon alfa-2a and ribavirin at the discretion of the
             prescribing physician

          -  HCV infection

        Exclusion Criteria:

          -  None specified
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ried-innkreis</city>
        <zip>4910</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 31, 2015</lastchanged_date>
  <firstreceived_date>July 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
